Clinical trials: NASH - Nonalcoholic Steatohepatitis, open to volunteers
- Condition NASH - Nonalcoholic Steatohepatitis
- Status Open to volunteers
- Accepts healthy volunteers yes
Obesity, Weight Loss
Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue.
- Conditions
- Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis
- Trial name
- NCT02933554
- Testing
- Embospheres Microspheres
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Keith Pereira, MD:
Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin…
- Conditions
- Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
- Trial name
- NCT04232566
- Testing
- Bariatric surgery
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Obesity, Morbid, Metabolic Syndrome
Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach
Variable outcomes after weight loss surgery are likely attributable to complex, poorly understood mechanisms. Due to the significant impact that morbid obesity has on a patient's health, successful management of obesity and its…
- Conditions
- Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT04841057
- Testing
- 50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Nonalcoholic Fatty Liver Disease
Observational Study About Patients Diagnosed With NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome.
- Trial name
- NCT05625750
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Obesity, Nonalcoholic Fatty Liver
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
- Trial name
- ATM (NCT06335771)
- Testing
- Dietary consultation weight loss intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
Nonalcoholic Steatohepatitis (NASH)
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of IMM-H014 on fasted condition, and characterize PK of IMM-H014 on an empty stomach (fasted condition) and…
- Trial name
- NCT06216041
- Testing
- IMM-H014, IMM-H014 ( FE)
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Steatohepatitis, Nonalcoholic
The COherence of Scatter Identification and Exclusion Algorithm Study
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040.
- Trial name
- COSIE (NCT06975579)
- Testing
- Ultrasound image processing
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Diabetes Mellitus, Type 2, PreDiabetes
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR).
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes, Insulin Resistance, Obesity
- Trial name
- NCT05165706
- Testing
- Dietary Intervention Mediterranean Low Carbohydrate Diet, Dietary Intervention Standard Low Carbohydrate Diet, Dietary Intervention Standard Low Fat Diet
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Stanford University
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity.
- Trial name
- QUS in NASH (NCT03572465)
- Testing
- Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-Alcoholic Fatty Liver Disease, Gallstone Disease
Prevention of NAFLD and CVD Through Lifestyle Intervention
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid…
- Trial name
- MAUCO+ (NCT05618626)
- Testing
- Physical exercise and dietary intervention for NAFLD
- Where
- Chile
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Thermoacoustic Method for Estimating Liver Fat Fraction
The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements.
- Trial name
- NCT07321925
- Testing
- Thermoacoustic Enhanced Ultrasound
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Endra Lifesciences
Diabetes Mellitus Type 2, Diabetes Mellitus Type 1, NAFLD - Nonalcoholic Fatty Liver Disease
Kuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) Program
Kuwait and the Gulf Region lack large longitudinal studies that identify risk factors dictating the onset of prediabetes and the progression to diabetes.
- Conditions
- Diabetes Mellitus Type 2, Diabetes Mellitus Type 1, NAFLD - Nonalcoholic Fatty Liver Disease, PreDiabetes
- Trial name
- KADEM (NCT06115876)
- Where
- Kuwait
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Dasman Diabetes Institute
Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease.
- Trial name
- NCT07149571
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Hyperuricemia, NAFLD (Nonalcoholic Fatty Liver Disease)
Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients
1. Identifying the association between hyperuricemia and NAFLD can lead to early detection and prevention of liver fibrosis in adult obese patients. 2.
- Conditions
- Hyperuricemia, NAFLD (Nonalcoholic Fatty Liver Disease), Liver Fibrosis
- Trial name
- NCT07168551
- Testing
- *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level ., *Imaging Studies:* 1- Ultrasound 2 - FibroScan, Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
NAFLD (Nonalcoholic Fatty Liver Disease)
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.
- Trial name
- NCT06932289
- Testing
- Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF), The integrated sweat sensor and vascular sensor (wearable), continuous glucose monitor (CGM)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Greater Los Angeles Healthcare System